Clinical Trials Browser

Interventional × Breast Neoplasms × Cetuximab × Clear all

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07318805 2026-01-06

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

260 enrolled

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT07216105 2025-12-17

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Phase 1 Recruiting

113 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05226871 2025-11-25

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Phase 2 Active not recruiting

35 enrolled

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms

NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Phase 1 Active not recruiting

155 enrolled

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT00248287 2025-01-29

CA225200

Phase 2 Active not recruiting

154 enrolled 12 charts

Breast

Breast Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

5 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT01097642 2021-09-22

ICE

Phase 2 Completed

40 enrolled 11 charts

Breast

Breast Neoplasms

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Phase 1/2 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03552406 2021-05-06

Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

Phase 1 Unknown

33 enrolled

BreastHead & Neck

Breast Neoplasms, Head and Neck Neoplasms

NCT02124148 2020-04-01

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

Phase 1 Completed

167 enrolled

BreastGastrointestinal

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT02318901 2019-10-21

PembroMab

Phase 1/2 Terminated

16 enrolled 6 charts

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT00622674 2017-12-02

Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

37 enrolled

BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT00232505 2017-06-28

Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

Phase 2 Completed

112 enrolled 13 charts

Breast

Breast Neoplasms

NCT00275041 2016-12-13

Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

21 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00633464 2016-03-10

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Phase 2 Completed

79 enrolled 15 charts

Breast

Breast Neoplasms

NCT00600249 2014-03-20

Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

Phase 2 Completed

35 enrolled

Breast

Breast Neoplasms

NCT00463788 2014-02-13

BALI-1

Phase 2 Completed

181 enrolled 15 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00353717 2009-01-13

Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma

Phase 1/2 Unknown

25 enrolled

Breast

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

Clinical Trials

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

CA225200

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

ICE

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

PembroMab

Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

BALI-1

Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma